Literature DB >> 6289359

Human brain receptor alterations in suicide victims.

L R Meyerson, L P Wennogle, M S Abel, J Coupet, A S Lippa, C E Rauh, B Beer.   

Abstract

A comparison was made of human postmortem muscarinic-cholinergic, beta-adrenergic and serotonergic (presynaptic) recognition sites in cortical tissues derived from suicide and homicide (control) victims. An elevation of 47% and 35% in the suicide group compared to controls was observed in receptor ligand binding for 3H-quinuclidinyl benzilate (QNB, muscarinic antagonist) and 3H-imipramine (IMI, a presynaptic serotonin marker), respectively. In contrast, no appreciable differences in 3H-dihydroalprenolol (DHA, beta-adrenergic antagonist) binding were observed between the two groups. Additionally, tissues from both groups of subjects were analyzed for tricyclic antidepressive agent (TAD) content. High performance liquid chromatographic (HPLC) tissue analysis revealed no detectable levels of tricyclic agents with an assay sensitivity of 50 picograms/mg tissue. The results presented herein demonstrate neurotransmitter-receptor alterations in suicide subjects compared to homicide (control) victims. The attendant roles of serotonergic and muscarinic-cholinergic processes in the psychobiology of suicide and depression are addressed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289359     DOI: 10.1016/0091-3057(82)90279-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.

Authors:  J J Mann; R A Henteleff; T F Lagattuta; J A Perper; S Li; V Arango
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Serotonin transport kinetics correlated between human platelets and brain synaptosomes.

Authors:  Jeffrey L Rausch; Maria E Johnson; Junqing Li; Julian Hutcheson; Benjamin M Carr; Katina M Corley; Amanda B Gowans; Joseph Smith
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

Review 3.  Genetic and pharmacological models of cholinergic supersensitivity and affective disorders.

Authors:  D H Overstreet; R W Russell; A D Crocker; J C Gillin; D S Janowsky
Journal:  Experientia       Date:  1988-06-15

Review 4.  Platelet research in psychiatry.

Authors:  A Wirz-Justice
Journal:  Experientia       Date:  1988-02-15

5.  NEUROBIOLOGY OF ADULT AND TEENAGE SUICIDE.

Authors:  Ghanshyam N Pandey
Journal:  Asian J Psychiatr       Date:  2011-03-01

6.  Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.

Authors:  C B Brink; J D Clapton; B E Eagar; B H Harvey
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

Review 7.  Biological basis of suicide and suicidal behavior.

Authors:  Ghanshyam N Pandey
Journal:  Bipolar Disord       Date:  2013-06-15       Impact factor: 6.744

8.  Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells.

Authors:  Christiaan B Brink; Susanna L Viljoen; Susanna E de Kock; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2004-06       Impact factor: 3.584

9.  Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice.

Authors:  Katarzyna Socała; Dorota Nieoczym; Elżbieta Wyska; Ewa Poleszak; Piotr Wlaź
Journal:  J Neural Transm (Vienna)       Date:  2012-01-04       Impact factor: 3.575

10.  Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.

Authors:  Andrew Stuart Gibbons; Won Je Jeon; Elizabeth Scarr; Brian Dean
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.